CSL Limited is an Australian biotechnology company specializing in rare and serious diseases, influenza vaccines, and treatments for iron deficiency and nephrology. It comprises three main segments: CSL Behring, which focuses on plasma products, gene therapies, and recombinants; CSL Seqirus, dedicated to influenza vaccines and pandemic services; and CSL Vifor, which targets iron deficiency and nephrology therapeutics. The company also has a plasma collection network, CSL Plasma, with over 325 centers across the United States, Europe, and China.
Operating globally, with a presence in Australia, the United States, Germany, the UK, Switzerland, and China, CSL Limited offers products like Respreeza, Zemaira, HAEGARDA, KCENTRA, and Hepatitis B immunoglobulins, among others. Founded in 1991, the company has grown to employ over 32,000 people worldwide.
Overview
CSL is one of Australia’s largest healthcare companies, with businesses spanning plasma-derived medicines, vaccines and treatments for iron deficiency and kidney disease. Its scale and 5.50% revenue growth sit alongside a more difficult earnings picture: the supplied figures show negative earnings per share and a negative profit margin. That contrast makes CSL a story of specialised global healthcare operations as well as the challenge of assessing current profitability.
CSL is a Melbourne-headquartered healthcare company whose biotechnology operations reach Australia and international markets. CSL Behring makes plasma products, gene therapies and recombinant medicines; CSL Seqirus supplies influenza-related products and pandemic services; and CSL Vifor focuses on iron deficiency and nephrology. This mix gives the group exposure to specialised therapies and vaccines, with research, manufacturing and distribution central to its business.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Key facts
- Ticker
- CSL
- Exchange
- AU
- ISIN
- AU000000CSL8
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Currency
- AUD
- Price
- A$181.77
- Previous close
- A$181.99
- Day change
- -A$0.22 (-0.12%)
- Market cap
- 87.3B
- 52W low
- A$88.83
- 52W high
- A$216.78
Price and trend
Last price: A$181.77
- Price
- A$181.77
- 52W range
- A$88.83 – A$216.78
- 50-day SMA
- A$162.43
- 200-day SMA
- A$142.54
- Price vs 50D SMA
- 11.91%
- Price vs 200D SMA
- 27.52%
Valuation
- P/E
- 0.00
- PEG
- 1.82
- EPS
- -7.90
- Dividend yield
- 1.63%
- Beta
- 0.08
CSL’s market capitalisation is A$84.1B, while the supplied revenue figure is A$15.8B and revenue growth is 5.50%. The reported P/E ratio is 0 and earnings per share is negative A$7.51, alongside a negative 16.33% profit margin. In this context, the P/E figure is not a useful standalone measure of valuation; investors need to consider the reported loss and the company’s longer-term ability to convert its specialised products and research into sustainable earnings. The indicated dividend yield is 1.64%, but it does not remove the uncertainty around profitability.
Profitability and growth
- Revenue growth
- 5.50%
- Revenue TTM
- 15.8B
- Profit margin
- -16.33%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
- Price
- A$181.77
- Target price
- A$183.99
- Target vs last price
- 1.22% from last price
The supplied target price is A$184.80, equivalent to 5.39% from the last price of A$175.35. This is secondary context rather than a measure of business quality: expectations can change, and the supplied figures show current profitability challenges that investors may weigh alongside CSL’s specialised healthcare portfolio and revenue growth.
Risks
CSL operates across complex, regulated areas of healthcare, where product safety, clinical outcomes, approvals and manufacturing reliability matter. Its plasma-derived medicines and vaccines also expose the business to supply-chain and operational challenges, while its international reach brings varied market and currency conditions. The supplied figures show negative earnings per share and a negative profit margin, making current profitability an important consideration. The share price remains within a wide 52-week range, and its recent position above both moving averages may change as market conditions and company performance evolve.
FAQ
What does CSL do?
CSL develops, manufactures and distributes biopharmaceutical products and vaccines. Its businesses span plasma-derived medicines and gene therapies, influenza vaccines and pandemic services, and treatments related to iron deficiency and kidney disease.
Does CSL pay a dividend?
The supplied figures show a dividend yield of 1.64% and a dividend per share of A$2.92. A yield can change as the share price moves, and these figures do not establish what future distributions will be.
How has CSL’s share price compared with its moving averages?
At A$175.35, the share price was 10.42% above its 50-day moving average of A$158.81 and 23.09% above its 200-day moving average of A$142.46. These measures give recent price context but do not determine future performance.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
CSL Limited (ASX: CSL) Fundamentals
